PHEN Clinical Trials Rally

Increasing the participation of African American men in prostate cancer clinical trials through education, awareness, support and collaborations. This portal provides clinical trials background information, details for specific trials, personal stories and other resources to support the Rally.

This information is not intended as medical advice for patients. Patients should consult their medical doctor for advice and recommendations about specific clinical trials.


"We must not be left behind with new prostate cancer treatments."

PHEN president and founder Thomas A. Farrington talks about his prostate cancer journey and the importance of African American men participating in clinical trials.

Information

Understanding the possible benefits for patients when participating in a clinical trial.

Clinical trials offer important and unique benefits to patients.

Information

Dr. J. Carter Presents Clinical Trials 101

Dr. Carter's brief video presentations provide basic information for patients to better understand clinical trials.

Information

What Are Clinical Trials?

Information that all patients need to know when considering enrolling into a clinical trial.

Information

A Clinical Trials Guide for Patients

Patient information on why clinical trials matter, how clinical trials work, what to expect, myths and facts. Information provided by Sanofi.

Information
<B> AMG 509 </b>


AMG 509

This clinical trial is for patients who have metastatic castration resistant prostate cancer (mCRPC) and failed to respond to abiraterone acetate or enzalutamide (but not both) and to taxane-based chemotherapy.

Information

<b> AMG 160 </b>


AMG 160

This study is investigating the safety and effects (good or bad) of using AMG 160 alone or with pembrolizumab (Keytruda) to treat metastatic castration resistant prostate cancer (mCRPC), which has spread to other parts of the body and is resistant to standard hormonal therapies.

Information


Checkmate 650

This clinical trial is for patients who have metastatic castration resistant Prostate Cancer (mCPRC) that has progressed while on Docetaxel. This trial is investigating the safety and effects (good or bad) of specific doses of Ipilimumab along with Nivolumab in patients with prostate cancer. Nivolumab and ipilimumab are investigational immunotherapies, which means that they are not currently approved to treat metastatic prostate cancer.

Information
<b>CheckMate 7DX</b>


CheckMate 7DX

The purpose of this study is to test the safety and efficacy of nivolumab with docetaxel in men with advanced castration resistant prostate cancer (mCRPC), who have progressed after second-generation hormonal manipulation. Patients eligible to participate in this study will receive Nivolumab, docetaxel, and prednisone or docetaxel, prednisone, and placebo.

Information

<b> Amplitude </b>


Amplitude

The AMPLITUDE study is looking for men with newly diagnosed metastatic prostate cancer.

Information

<b> APA RP </b>


APA RP

The APA RP study is looking for men with prostate cancer at high risk of metastasis and who have recently undergone or are planning to undergo radical prostatectomy (RP) surgery.

Information


MAGNITUDE

The MAGNITUDE Study is a Phase 3 randomized, placebo-controlled, double-blind study comparing a combination of an investigational medicine and standard treatment , to a combination of a placebo and standard treatment for men with metastatic prostate cancer.

Information

PROTEUS

The PROTEUS study is a randomized, double-blind, placebo-controlled, phase 3 study of an investigational drug in subjects with high-risk, localized or locally advanced prostate cancer who are candidates for radical prostatectomy.

Information
<B> SPLASH </B>


SPLASH

This trial is for male patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT) but who haven't yet received chemotherapy for mCRPC.

Information

<b>P-PSMA-101</b>


P-PSMA-101

This clinical trial is for patients with metastatic castration-resistant prostate cancer (mCRPC) that has worsened despite having received hormonal and chemotherapeutic treatments.

Information


TALAPRO-2

This trial is for patients with metastatic Castration-Resistant Prostate Cancer who have not received prior treatment for Castrate-Resistant disease.

Information

Low Risk Prostate Cancer

Clinical trials for patients who are diagnosed with low risk prostate cancer (Gleason 6). Patients may be interested in active surveillance or making a decision to begin active treatment.

Information

Intermediate Risk Prostate Cancer

Clinical trials for patients who are diagnosed with intermediate risk prostate cancer (Gleason 7). Patients may be interested in active surveillance or making a decision to begin active treatment.

Information

High Risk Prostate Cancer

Clinical trials for patients diagnosed with high risk prostate cancer (Gleason 8 - 10). Patients may be deciding on an active treatment protocol.

Information

Biochemical Recurrence of Prostate Cancer

Clinical trials for patients who have a recurrence of prostate cancer following primary treatment with surgery or radiation. These patients have not yet begun treatment with androgen deprivation therapy or are interested in quality of life studies.

Information

Non-Metastatic Castration Resistant Prostate Cancer (nMCRPC)

Clinical trials for patients whose PSA rises while they are on androgen deprivation therapy but prostate cancer has not metastasized.

Information

Metastatic Castration Resistant Prostate Cancer (MCRPC)

Clinical trials for patients diagnosed with metastatic prostate cancer that no longer responds to androgen deprivation treatment. Patients who are seeking treatment options following a diagnosis of MCRPC.

Information

Metastatic Castration Sensitive Prostate Cancer (MCSPC)

Clinical trials for patients with prostate cancer which has spread to other parts of the body but still respond to medical or surgical treatments that lowers testosterone

Information
























PHEN,Inc. © 2022 All rights reserved